公开(公告)号：US20100267814A1

公开(公告)日：2010-10-21

申请号：US12740211

申请日：2008-10-29

Applicant: C. Frank Bennett ,  Ayelet Chajut ,  Christine Esau ,  Eric G. Marcusson ,  Noga Yerushalmi

Inventor： C. Frank Bennett ,  Ayelet Chajut ,  Christine Esau ,  Eric G. Marcusson ,  Noga Yerushalmi

IPC: A61K31/7125 ,  A61K31/7088 ,  A61K31/712 ,  A61K31/7115 ,  A61P35/00

CPC classification number: C12N15/113 ,  A61K31/407 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K31/7088 ,  A61K31/7105 ,  A61K45/06 ,  C12N2310/113 ,  C12N2310/141 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/346 ,  C12N2310/3525

Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.

Abstract translation: 本文提供了用于治疗肝癌的方法。 这些方法包括施用包含修饰的寡核苷酸的化合物，其中修饰的寡核苷酸靶向于miRNA。 本文还提供了用于治疗肝癌的组合物。 这样的组合物包括包含修饰的寡核苷酸的化合物，其中修饰的寡核苷酸靶向于miRNA。 某些miRNA已被鉴定为在肝癌中过度表达，例如肝细胞癌，因此被选择用修饰的寡核苷酸靶向。 此外，某些miRNA已被鉴定为在暴露于二恶英的肝细胞癌细胞中过表达，因此被选择用修饰的寡核苷酸靶向。 已经发现某些这些miRNA的反义抑制抑制细胞增殖并诱导细胞凋亡。

公开(公告)号：US20090298174A1

公开(公告)日：2009-12-03

申请号：US12345780

申请日：2008-12-30

Applicant: Christine Esau ,  Bridget Lollo ,  C. Frank Bennett ,  Susan M. Freier ,  Richard H. Griffey ,  Brenda F. Baker ,  Timothy A. Vickers ,  Eric G. Marcusson ,  Erich Koller ,  Eric E. Swayze ,  Ravi Jain ,  Balkrishen Bhat ,  Eigen Peralta

Inventor： Christine Esau ,  Bridget Lollo ,  C. Frank Bennett ,  Susan M. Freier ,  Richard H. Griffey ,  Brenda F. Baker ,  Timothy A. Vickers ,  Eric G. Marcusson ,  Erich Koller ,  Eric E. Swayze ,  Ravi Jain ,  Balkrishen Bhat ,  Eigen Peralta

IPC: C12N5/00

CPC classification number: C12N15/113 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/31 ,  C12N2310/315 ,  C12N2310/317 ,  C12N2310/3181 ,  C12N2310/32 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/351 ,  C12N2310/3515 ,  C12N2320/11 ,  C12N2320/30 ,  C12N2320/50 ,  C12N2310/3525

Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.

公开(公告)号：US07595299B2

公开(公告)日：2009-09-29

申请号：US11089192

申请日：2005-03-24

Applicant: Anil Saksena ,  Viyyoor M. Girijavallabhan ,  Stephane L. Bogen ,  Raymond G. Lovey ,  Edwin Jao ,  Frank Bennett ,  Jinping L. McCormick ,  Haiyan Wang ,  Russell E. Pike ,  Yi-Tsung Liu ,  Tin-Yau Chan ,  Zhaoning Zhu ,  Ashok Arasappan ,  Kevin X. Chen ,  Srikanth Venkatraman ,  Tejal Parekh ,  Patrick A. Pinto ,  Bama Santhanam ,  F. George Njoroge ,  Ashit K. Ganguly ,  Henry A. Vaccaro ,  Scott Jeffrey Kemp ,  Odile Esther Levy ,  Marguerita Lim-Wilby ,  Susan Y. Tamura

Inventor： Anil Saksena ,  Viyyoor M. Girijavallabhan ,  Stephane L. Bogen ,  Raymond G. Lovey ,  Edwin Jao ,  Frank Bennett ,  Jinping L. McCormick ,  Haiyan Wang ,  Russell E. Pike ,  Yi-Tsung Liu ,  Tin-Yau Chan ,  Zhaoning Zhu ,  Ashok Arasappan ,  Kevin X. Chen ,  Srikanth Venkatraman ,  Tejal Parekh ,  Patrick A. Pinto ,  Bama Santhanam ,  F. George Njoroge ,  Ashit K. Ganguly ,  Henry A. Vaccaro ,  Scott Jeffrey Kemp ,  Odile Esther Levy ,  Marguerita Lim-Wilby ,  Susan Y. Tamura

IPC: A61K38/00

CPC classification number: C07K7/06 ,  A61K31/16 ,  A61K31/195 ,  A61K31/27 ,  A61K31/357 ,  A61K31/385 ,  A61K31/403 ,  A61K31/4164 ,  A61K31/445 ,  A61K38/05 ,  C07C205/51 ,  C07K5/101 ,  C07K7/02 ,  A61K2300/00

Abstract: The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract translation: 本发明公开了具有HCV蛋白酶抑制活性的新型肽化合物及其制备方法。 在另一个实施方案中，本发明公开了包含这些化合物的药物组合物以及使用它们来治疗与HCV蛋白酶相关的病症的方法。

公开(公告)号：US07425576B2

公开(公告)日：2008-09-16

申请号：US11644708

申请日：2006-12-21

Applicant: Ashok Arasappan ,  F. George Njoroge ,  Angela I. Padilla-Acevedo ,  Kevin X. Chen ,  Frank Bennett ,  Mousumi Sannigrahi ,  Stephane L. Bogen ,  Srikanth Venkatraman ,  Edwin E. Jao ,  Anil K. Saksena ,  Viyyoor M. Girijavallabhan

Inventor： Ashok Arasappan ,  F. George Njoroge ,  Angela I. Padilla-Acevedo ,  Kevin X. Chen ,  Frank Bennett ,  Mousumi Sannigrahi ,  Stephane L. Bogen ,  Srikanth Venkatraman ,  Edwin E. Jao ,  Anil K. Saksena ,  Viyyoor M. Girijavallabhan

IPC: A61K31/401 ,  C07D207/08

CPC classification number: C07D209/52 ,  A61K38/00 ,  C07K5/0202 ,  C07K5/06034 ,  C07K5/06078 ,  C07K5/06191 ,  C07K5/0808 ,  C07K5/0827

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract translation: 本发明公开了具有HCV蛋白酶抑制活性的新型化合物及其制备方法。 在另一个实施方案中，本发明公开了包含这些化合物的药物组合物以及使用它们来治疗与HCV蛋白酶相关的病症的方法。

公开(公告)号：US07423058B2

公开(公告)日：2008-09-09

申请号：US11645181

申请日：2006-12-21

Applicant: Stephane L. Bogen ,  Weidong Pan ,  Sumei Ruan ,  Kevin X. Chen ,  Ashok Arasappan ,  Srikanth Venkatraman ,  Latha G. Nair ,  Mousumi Sannigrahi ,  Frank Bennett ,  Anil K. Saksena ,  F. George Njoroge ,  Viyyoor M. Girijavallabhan

Inventor： Stephane L. Bogen ,  Weidong Pan ,  Sumei Ruan ,  Kevin X. Chen ,  Ashok Arasappan ,  Srikanth Venkatraman ,  Latha G. Nair ,  Mousumi Sannigrahi ,  Frank Bennett ,  Anil K. Saksena ,  F. George Njoroge ,  Viyyoor M. Girijavallabhan

IPC: A61K31/401 ,  C07D207/08

CPC classification number: C07D209/52 ,  A61K38/00 ,  C07D209/02 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07K5/0205 ,  C07K5/0808 ,  C07K5/0812 ,  C07K5/0827

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract translation: 本发明公开了具有HCV蛋白酶抑制活性的新型化合物及其制备方法。 在另一个实施方案中，本发明公开了包含这些化合物的药物组合物以及使用它们来治疗与HCV蛋白酶相关的病症的方法。

公开(公告)号：US07339051B2

公开(公告)日：2008-03-04

申请号：US10831901

申请日：2004-04-26

Applicant: Stanley T. Crooke ,  David J. Ecker ,  Rangarajan Sampath ,  Susan M. Freier ,  Christian Massire ,  Steven A. Hofstadler ,  Kristin Sannes Lowery ,  Eric E. Swayze ,  Brenda F. Baker ,  C. Frank Bennett

Inventor： Stanley T. Crooke ,  David J. Ecker ,  Rangarajan Sampath ,  Susan M. Freier ,  Christian Massire ,  Steven A. Hofstadler ,  Kristin Sannes Lowery ,  Eric E. Swayze ,  Brenda F. Baker ,  C. Frank Bennett

IPC: C07H21/02 ,  C07H21/04

CPC classification number: C12N15/1131 ,  C07K16/10 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

Abstract: The present invention provides design and synthesis of oligomeric compounds and compositions that can be administered to reduce the activity of SARS virus in vivo or in vitro, to prevent or treat SARS virus-associated disease, to detect AARS virus, and to diagnose SARS virus-associated diseases.

Abstract translation: 本发明提供可以施用以降低SARS病毒在体内或体外的活性，预防或治疗SARS病毒相关疾病，检测AARS病毒和诊断SARS病毒的寡聚化合物和组合物的设计和合成， 相关疾病

公开(公告)号：US07186747B2

公开(公告)日：2007-03-06

申请号：US11065531

申请日：2005-02-24

Applicant: Ashok Arasappan ,  F. George Njoroge ,  Angela I. Padilla-Acevedo ,  Kevin X. Chen ,  Frank Bennett ,  Mousumi Sannigrahi ,  Stephane L. Bogen ,  Srikanth Venkatraman ,  Edwin Jao ,  Anil K. Saksena ,  Viyyoor M. Girijavallabhan

Inventor： Ashok Arasappan ,  F. George Njoroge ,  Angela I. Padilla-Acevedo ,  Kevin X. Chen ,  Frank Bennett ,  Mousumi Sannigrahi ,  Stephane L. Bogen ,  Srikanth Venkatraman ,  Edwin Jao ,  Anil K. Saksena ,  Viyyoor M. Girijavallabhan

IPC: A61K31/401 ,  C07D207/08

CPC classification number: C07D209/52 ,  A61K38/00 ,  C07K5/0202 ,  C07K5/06034 ,  C07K5/06078 ,  C07K5/06191 ,  C07K5/0808 ,  C07K5/0827

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract translation: 本发明公开了具有HCV蛋白酶抑制活性的新型化合物及其制备方法。 在另一个实施方案中，本发明公开了包含这些化合物的药物组合物以及使用它们来治疗与HCV蛋白酶相关的病症的方法。

公开(公告)号：US07169760B2

公开(公告)日：2007-01-30

申请号：US09909012

申请日：2001-07-19

Applicant: Anil K. Saksena ,  Viyyoor Moopil Girijavallabhan ,  Stephane L. Bogen ,  Raymond G. Lovey ,  Edwin Jao ,  Frank Bennett ,  Jinping L. Mc Cormick ,  Haiyan Wang ,  Russell E. Pike ,  Yi-Tsung Liu ,  Tin-Yau Chan ,  Zhaoning Zhu ,  Ashok Arasappan ,  Kevin X. Chen ,  Srinkanth Venkatraman ,  Tejal Parekh ,  Patrick A. Pinto ,  Bama Santhanam ,  F. George Njoroge ,  Ashit K. Ganguly ,  Henry A. Vaccaro ,  Scott Jeffrey Kemp ,  Odile Esther Levy ,  Marguerita Lim-Wilby ,  Susan Y. Tamura

Inventor： Anil K. Saksena ,  Viyyoor Moopil Girijavallabhan ,  Stephane L. Bogen ,  Raymond G. Lovey ,  Edwin Jao ,  Frank Bennett ,  Jinping L. Mc Cormick ,  Haiyan Wang ,  Russell E. Pike ,  Yi-Tsung Liu ,  Tin-Yau Chan ,  Zhaoning Zhu ,  Ashok Arasappan ,  Kevin X. Chen ,  Srinkanth Venkatraman ,  Tejal Parekh ,  Patrick A. Pinto ,  Bama Santhanam ,  F. George Njoroge ,  Ashit K. Ganguly ,  Henry A. Vaccaro ,  Scott Jeffrey Kemp ,  Odile Esther Levy ,  Marguerita Lim-Wilby ,  Susan Y. Tamura

IPC: A61K38/05 ,  A61K31/44 ,  A61K31/16 ,  A61K31/227

CPC classification number: C07K7/06 ,  A61K31/16 ,  A61K31/195 ,  A61K31/27 ,  A61K31/357 ,  A61K31/385 ,  A61K31/403 ,  A61K31/4164 ,  A61K31/445 ,  A61K38/05 ,  C07C205/51 ,  C07K5/101 ,  C07K7/02 ,  A61K2300/00

Abstract: The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract translation: 本发明公开了具有HCV蛋白酶抑制活性的新型肽化合物及其制备方法。 在另一个实施方案中，本发明公开了包含这些化合物的药物组合物以及使用它们来治疗与HCV蛋白酶相关的病症的方法。

公开(公告)号：US07132530B2

公开(公告)日：2006-11-07

申请号：US10633843

申请日：2003-08-04

Applicant: C. Frank Bennett ,  Kenneth Dobie

Inventor： C. Frank Bennett ,  Kenneth Dobie

IPC: C07H21/04

CPC classification number: C12N15/1137 ,  A61K38/00 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525 ,  C12Y115/01001 ,  Y02P20/582

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.

公开(公告)号：US07122649B2

公开(公告)日：2006-10-17

申请号：US10755109

申请日：2004-01-09

Applicant: Muthiah Manoharan ,  Phillip Dan Cook ,  Clarence Frank Bennett

Inventor： Muthiah Manoharan ,  Phillip Dan Cook ,  Clarence Frank Bennett

IPC: C07H21/04 ,  C07H21/00 ,  C12Q1/68 ,  A01N61/00 ,  A01N43/04

CPC classification number: C07H21/04 ,  C07J1/00 ,  C12N2710/20022 ,  H04J2203/0042 ,  H04J2203/006

Abstract: Linked nucleosides having at least one functionalized nucleoside that bears a substituent such as a steroid molecule, a reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme, a peptide, a protein, a water soluble vitamin, a lipid soluble vitamin, an RNA cleaving complex, a metal chelator, a porphyrin, an alkylator, a pyrene, a hybrid photonuclease/intercalator, or an aryl azide photo-crosslinking agent exhibit increased cellular uptake and other properties. The substituent can be attached at the 2′-position of the functionalized nucleoside via a linking group. If at least a portion of the remaining liked nucleosides are 2′-deoxy-2′-fluoro, 2′-O-methoxy, 2′-O-ethoxy, 2′-O-propoxy, 2′-O-aminoalkoxy or 2′-O-allyloxy nucleosides, the substituent can be attached via a linking group at any of the 3′ or the 5′ positions of the nucleoside or on the heterocyclic base of the nucleoside or on the inter-nucleotide linkage linking the nucleoside to an adjacent nucleoside.